Ginkgo Bioworks (NYSE: DNA) net income
Ginkgo Bioworks reported a net loss of $312.8m for fiscal 2025; in fiscal 2024 it reported a net loss of $547.0m. Earnings per share were −$5.64.
Ginkgo Bioworks's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$312.8m | — | −183.8% | −$5.64 |
| 2024 | −$547.0m | — | −240.9% | −$10.54 |
| 2023 | −$892.9m | — | −355.1% | −$0.46 |
| 2022 | −$2,105m | — | −440.6% | −$1.25 |
| 2021 | −$1,830m | — | −583.1% | −$1.35 |
| 2020 | −$126.6m | — | −165.2% | −$0.10 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Ginkgo Bioworks net income compared with its sector
By net income for its latest fiscal year, Ginkgo Bioworks ranks 451st of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Ginkgo Bioworks, −183.8%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 449th | Praxis Precision Medicines | −$303.3m | — |
| 450th | Kymera Therapeutics | −$311.4m | −794.0% |
| 451st | Ginkgo Bioworks | −$312.8m | −183.8% |
| 452nd | Replimune Group | −$313.9m | — |
| 453rd | Cogent Biosciences | −$328.9m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Ginkgo Bioworks
- How much did Ginkgo Bioworks earn in fiscal 2025?
- Ginkgo Bioworks reported a net loss of $312.8m for fiscal 2025. In fiscal 2024 it reported a net loss of $547.0m.
- What are the earnings per share of Ginkgo Bioworks?
- They were −$5.64 in fiscal 2025, compared with −$10.54 in fiscal 2024.
- Where does Ginkgo Bioworks rank in its sector by net income?
- It ranks 451st of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Ginkgo Bioworks come from?
- From the annual report (Form 10-K) that Ginkgo Bioworks files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Ginkgo Bioworks files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Ginkgo Bioworks: the Ginkgo Bioworks page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.